[go: up one dir, main page]

EP2912163A1 - Streptococcus thermophilus strains for treating helicobacter pylori infection - Google Patents

Streptococcus thermophilus strains for treating helicobacter pylori infection

Info

Publication number
EP2912163A1
EP2912163A1 EP12791860.5A EP12791860A EP2912163A1 EP 2912163 A1 EP2912163 A1 EP 2912163A1 EP 12791860 A EP12791860 A EP 12791860A EP 2912163 A1 EP2912163 A1 EP 2912163A1
Authority
EP
European Patent Office
Prior art keywords
pylori
strain
strains
infected
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12791860.5A
Other languages
German (de)
French (fr)
Inventor
Peggy Garault
Raphaelle Bourdet-Sicard
Francis MEGRAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Original Assignee
Gervais Danone SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone SA filed Critical Gervais Danone SA
Publication of EP2912163A1 publication Critical patent/EP2912163A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/21—Streptococcus, lactococcus
    • A23V2400/249—Thermophilus

Definitions

  • the present invention relates to the field of probiotics. Particularly, the invention pertains to the use of a strain of Streptococcus thermophilics for the treatment or the prevention of Helicobacter pylori infection.
  • probiotics are living micro-organisms which upon ingestion in a sufficient amount exert health benefits beyond basic nutrition.
  • Probiotic bacteria have been described among species belonging to the genera Lactobacillus, Bifidobacterium, Streptococcus and Lactococcus, commonly used in the dairy industry. Probiotics are thought to intervene at the level of the gut microbiota by impeding the development of pathogenic microorganisms and/or by acting more directly on the immune system.
  • H. pylori is a Gram-negative spiral-shaped bacteria that colonizes the human gastric mucus layer of more than 50% of the world's population. While the majority of individuals infected with H. pylori is asymptomatic although their gastric epithelium show sign of inflammation, 15% to 20% of H. pylori infected individuals develop diseases. Indeed, H. pylori is the major causative agent of chronic active gastritis, peptic ulcer diseases, atrophy, metaplasia, dysplasia, gastric cancer and gastric mucosa associated lymphoid tissue (MALT) lymphoma (see for review Fox and Wang, 2007 and Polk and Peek, 2010).
  • MALT lymphoid tissue
  • H. pylori binds specifically to gastric epithelial cells lining the gastric epithelium through several adhesion molecules (adhesins) produced by the bacteria, such as BabA and SabA proteins. Adhesion to the gastric epithelial cells protects the bacteria from liquid flow, peristaltic movement and shedding of the mucous layer. H. pylori adhesion to the gastric mucosa induces signal transduction pathways within the gastric epithelial cells, leading to gastric epithelial cell damages and atrophy via oxidative stress, apoptosis and/or autophagy mechanisms. Accordingly, H. pylori adhesion to gastric epithelial cells is a key step in the establishment of an infection of the gastric mucosa.
  • H. pylori The standard treatment in patients infected with H. pylori is two antibiotics associated to a proton pump inhibitor (PPI), so called triple therapy.
  • PPI proton pump inhibitor
  • H. pylori eradication rate following triple therapy is dropping down because of antibiotic resistance or poor compliance.
  • probiotics have been proposed as alternatives or complements to triple therapy for treating or preventing H. pylori infection.
  • Lactobacillus reuteri is considered as a candidate probiotic for inhibiting the growth of H. pylori since it produces the potent antimicrobial substance reuterin (3-hydroxypropionaldehyde) (International Application WO 2004/031368).
  • Boyanova et al. (2009) have found several Lactobacillus delbrueckii subsp. bulgaricus strains that inhibit the growth of H. pylori strains in vitro. Simova et al.
  • Lactobacillus delbrueckii strain (BB18) producing an inhibitory peptide (bacteriocin) and strongly inhibiting H. pylori.
  • Linsalata et al. (2004) found that the Lactobacillus brevis strain CD2 is capable of reducing the intragastric H. pylori load, and suggested that it might be due to the elevated arginine deiminase activity of this strain, which would deprive H. pylori of arginine, and inhibit their growth and proliferation.
  • the inventors have found that the bacterial species Streptococcus thermophilus (S. thermophilics) is capable of decreasing the load of H. pylori strains in vivo.
  • a subject of the present invention is a Streptococcus thermophilus strain for use for treating or preventing Helicobacter pylori infection.
  • Said Streptococcus thermophilus can be used as a medicament, including a pharmaceutical composition and a functional food.
  • Said S. thermophilus strain is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori.
  • said S. thermophilus strain is the strain CNCM 1-1520. This strain was deposited by the Applicant, according to the Budapest Treaty, at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Dondel Roux, Paris) on December 30, 1994. This strain is disclosed in International Application WO 96/20607. This strain is also referred to as DN-001 147.
  • the present invention also encompasses mutant strains or genetically transformed strains derived from the parent strain CNCM 1-1520, provided that they are capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori.
  • Method for assessing the capacity of a S. thermophilus strain to decrease the load of H. pylori strains in the stomach of a subject infected with H. pylori are described in the Examples below.
  • These mutant or genetically transformed strains can be strains wherein one or more endogenous gene(s) of the parent strain CNCM 1-1520 has (have) been mutated, for instance to modify some of their metabolic properties (e.g.
  • strains resulting from the genetic transformation of the parent strain CNCM 1-1520 by one or more gene(s) of interest for instance in order to give to said genetically transformed strains additional physiological features, or to allow them to express proteins of therapeutic or vaccinal interest that one wishes to administer through said strains.
  • mutant or genetically transformed strains can be obtained from the parent strain CNCM 1-1520 strain by means of the conventional techniques for random or site-directed mutagenesis and genetic transformation of Streptococcus, such as those described by Biswas et ah, 1993 and Maguin et ah, 1996, or by means of the technique known as "genome shuffling", such as described by Yu et al , 2008.
  • a subject of the present invention is also a cell fraction which can be obtained from a S. thermophilus strain capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori, preferably the strain CNCM 1-1520, provided that said cell fraction is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori, for use for treating or preventing H. pylori infection.
  • Said cell fraction is in particular DNA preparations or bacterial wall preparations obtained from cultures of said strain. It may also be culture supernatants or fractions of these strains.
  • the cell fractions suitable for this use can be chosen, for example, by testing their properties on the load of H. pylori strains in the stomach of a subject infected with H. pylori.
  • a subject of the present invention is also a composition comprising a Streptococcus thermophilus strain according to the present invention, preferably the strain CNCM 1-1520, or a cell fraction according to the present invention, for use for treating or preventing H. pylori infection.
  • said strain can be used in the form of whole bacteria which may be living or dead.
  • said strain can be used in the form of a bacterial lysate.
  • the bacterial cells are present as living, viable cells.
  • composition of the invention can be in any form suitable for administration, in particular oral administration. This includes for instance solids, semi-solids, liquids, and powders. Liquid composition are generally preferred for easier administration, for instance as drinks.
  • the composition can comprise at least 10 5 cfu, preferably at least 10 6 cfu, per gram dry weight, of at least one bacterial strain as mentioned above.
  • composition can further comprise other strains of Streptococcus thermophilus and/or other strains of bacteria than the strains according to the present invention, in particular probiotic strain(s), such as Lactobacillus, Bifidobacterium and Lactococcus strain(s).
  • probiotic strain(s) such as Lactobacillus, Bifidobacterium and Lactococcus strain(s).
  • the composition comprises the Streptococcus thermophilus strain CNCM 1-1520, the Streptococcus thermophilus strain CNCM 1-1521 (also referred to as DN-001 339) and the Lactobacillus bulgaricus strain CNCM 1-1519 (also referred to as DN-100 182), and optionally a Lactobacillus paracasei strain, preferably the Lactobacillus paracasei subsp. paracasei CMCM 1-1518 (also referred to as DN-1 14 001). All these strains are described in International Application WO 96/20607.
  • the composition may typically comprise 10 5 to 10 13 colony forming units (cfu), preferably at least 10 6 cfu, more preferably at least 10 7 cfu, still more preferably at least 10 8 cfu, and most preferably at least 10 9 cfu per gram dry weight of the composition.
  • this corresponds generally to 10 4 to 10 12 colony forming units (cfu), preferably at least 10 5 cfu, more preferably at least 10 6 cfu, still more preferably at least 10 7 cfu, and most preferably at least 10 9 cfu/ml.
  • the composition can be a pharmaceutical composition or a nutritional composition, including food products, food supplements and functional food. More particularly, the composition can be a medicament, including a pharmaceutical composition and a functional food.
  • a “food supplement” designates a product made from compounds usually used in foodstuffs, but which is in the form of tablets, powder, capsules, potion or any other form usually not associated with aliments, and which has beneficial effects for one's health.
  • a “functional food” is an aliment which also has beneficial effects for one's health.
  • food supplements and functional food can have a physiological effect - protective or curative - against a disease, for example against a chronic disease.
  • the nutritional composition according to the invention also includes a baby food, an infant milk formula or an infant follow-on formula.
  • the present composition is a nutraceutical or a pharmaceutical product, a nutritional supplement or medical food.
  • the composition can be a dairy product, preferably a fermented dairy product.
  • the fermented product can be present in the form of a liquid or present in the form of a dry powder obtained by drying the fermented liquid.
  • dairy products include fermented milk and/or fermented whey in set, stirred or drinkable form, cheese and yoghurt.
  • the fermented product can also be a fermented vegetable, such as fermented soy, cereals and/or fruits in set, stirred or drinkable forms.
  • the fermented product is a fresh product.
  • a fresh product which has not undergone severe heat treatment steps, has the advantage that the bacterial strains present are in the living form.
  • a subject of the present invention is also the use of a S. thermophilics strain as defined above, preferably the strain CNCM 1-1520, or a composition as defined above for the manufacture of a medicament for treating or preventing H. pylori infection.
  • a subject of the present invention is also a method for treating or preventing H. pylori infection in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a S. thermophilics strain as defined above, preferably the strain CNCM 1-1520, or a composition as defined above.
  • a subject of the present invention is also a method for the manufacture of a medicament for treating or preventing H. pylori infection, said method comprising incorporating a 5 * . thermophilus strain as defined above, preferably the strain CNCM I- 1520, or a cell fraction as defined above, into at least one pharmaceutically acceptable diluent, carrier or excipient.
  • the treatment or prevention encompasses inter alia: preventive infection and/or decreasing the load of H. pylori.
  • the treatment or prevention also encompasses addressing at least one of the symptoms associated with H. pylori mentioned below.
  • diagnosis of a H. pylori infection can be made by checking by a blood antibody test, a stool antigen test or the carbon urea breath test. It can also be made by biopsy under endoscopy followed by an urease test, a histological examination, a microbial culture or a quantitative Real-Time PCR. The symptoms or diseases associated with H.
  • pylori infection are stomach ache, abdominal pain, regurgitation, vomiting, belching, flatulence, nausea, chronic active gastritis, peptic ulcer diseases, atrophy, metaplasia, dysplasia, gastric cancer and gastric mucosa associated lymphoid tissue (MALT) lymphoma.
  • Figure 1 shows the change in the weight (in grams) of non infected mice, mice infected with H. pylori SSI receiving a control product, or infected with H. pylori SSI and treated with S. thermophilus strain CNCM 1-1520, measured just before the treatment (first bar), 3 weeks after the treatment (second bar) and just before sacrifice (third bar), obtained for 2 independent experiments.
  • Figure 2 shows the score of infection obtained by immunohistochemistry using anti-H. pylori antibodies in mice (i) non-infected with H. pylori, (ii) infected with H. pylori SSI receiving a control product (non- fermented milk) and (iii) infected with H. pylori SSI and treated with S. thermophilus CNCM 1-1520. Definition of scores: 0: no infected gland, 1 : rare infected glands, 2: 25% infected glands, 3 : from 25 to 50% infected glands, 4: > 50 % infected glands.
  • Figure 3 shows the quantification of H. pylori SSI DNA obtained by Real-Time
  • mice (i) non-infected with H. pylori, (ii) infected with H. pylori SSI but receiving a control product (non-fermented milk) and (iii) infected with H. pylori SSI and treated with S. thermophilus CNCM 1-1520.
  • Figure 4 shows the change in the weight (in grams) of non infected mice, mice infected with H. pylori SS I receiving a control product, or infected with H. pylori SSI and treated with S. thermophilus strain CNCM 1-1520, measured just before the treatment (first bar), 3 weeks after the treatment (second bar) and just before sacrifice (third bar), obtained for 2 independent experiments.
  • Figure 5 shows the quantification of H. pylori SS I obtained by bacterial culture on plate(in cfu (Colony Forming Unit) per gram of mice stomach) (i) non-infected with H. pylori, (ii) infected with H. pylori SS I but receiving a control product (non-fermented milk) and (iii) infected with H. pylori SS I and treated with S. thermophilus CNCM 1-1520.
  • EXAMPLE 1 EFFECT OF THE S. THERMOPHILUS STRAIN CNCM 1-1520 ON
  • H. pylori strain SS I having a very good colonization ability of mouse gastric mucosa (Lee et al., 1997) was used. Identity of the strain was checked by sequencing the genes glm, hspA and vacA (Raymond et al., 2004; Espinoza et al., 201 1 ; Zhang et al., 2007).
  • thermophilic strain CNCM 1-1520 was prepared as follows: First culture in M17 was prepared from frozen strain and incubated at 37°C for 17h. A second culture was prepared in skimmed milk enriched with yeast extract (2g/L) by inoculation at 1% from the first culture and incubated at 37°C for 17h. A third culture was prepared in milk enriched with yeast extract (2g/L) by inoculation at 1% from the second culture and incubation at 37°C until pH 4.7 was reached. The product was finally prepared by inoculation of milk enriched with yeast extract (2g/L) at 1% with the third culture until pH 4.8 was reached. Products were stored at -80°C. Bacterial count was carried out in Ml 7 after 48h incubation. Bacterial count was 1.5xl 0 9 cfu/mL.
  • mice of 5 weeks old (Charles River, France) and tested as SPF ( « specific pathogen free ») were split into groups: 2 groups of 15 mice were infected and 1 group of 10 mice was used as non infected control. Mice were fed with food poor in vitamins to enhance the lesion development induced by H. pylori.
  • mice received a hydric diet for 1 day and then were force-fed the following morning with 250 iL of an enriched suspension of the strain H. pylori SSI (1 to
  • mice 2 Petri dishes of H. pylori for 5 mice). The mice were put in a cage with a normal diet. Then, the mice received a hydric diet again in the evening. This protocol was repeated for
  • mice Eight weeks after their infection, mice were treated for 6 weeks with milk products containing S. thermophilics CNCM 1-1520. 120 g of milk product were given per cage per day in feeding-bottles instead of water. The feeding-bottles were changed every day. To assess the quantity of products ingested per animal, the feeding-bottles were weighed. Further, mice were weighted just before the treatment, 3 weeks after the treatment and just before sacrifice (results are shown in Figure 1).
  • mice control groups received milk enriched with yeast extract (2g/L) (/. e. , without any S. thermophilics strain).
  • mice were sacrificed by cervical dislocation. Laparotomy was performed. Stomachs were isolated and gastric mucosa was washed in physiological serum.
  • Stomach was cut through the middle from the esophagus to the duodenum.
  • cardia was eliminated, and then this half stomach was put in physiological serum to be used for the molecular study.
  • the left half stomach was used for histology.
  • the left half stomach was fixed 1 night in 3.7% formol and washed with 70% ethanol and then paraffin-embedded and sectioned at 3 ⁇ thickness.
  • Immunohistochemistry was carried out with an antibody anti-H. pylori antigens: primary antibody: anti-H. pylori (Dako, Ref. B0471); secondary antibody and DAB: Dako EnVision+ System-HRP (DAB) (Dako, Ref. K401 1).
  • Total DNA was extracted from the crushed stomach with Arrow Stool DNA kit (NorDiag, Norway) following supplier recommendations. For each crushed stomach total DNA was resuspended in 180 ⁇ TRIS buffer (lOmM).
  • Presence of DNA of H. pylori was quantified in DNA extracts by Real-Time PCR. Amplification was done with primers targeting 23 S rRNA gene, present in two copies in H. pylori following the method described by Oleastro et al. (2003).
  • primers targeting 23 S rRNA gene present in two copies in H. pylori following the method described by Oleastro et al. (2003).
  • For 20 ⁇ 1 of mix (MgCl 2 25mM, primers HPY-A et HPY-S 20 ⁇ described by Menard et al , 2002, sensor probe that is 5' labeled with LC-Red 640 and 3' phosphorylated and anchor probe that is 3 ' labeled with fluorescein (both probes described by Oleastro et al.
  • Amplification 50 cycles 20°C/sec
  • EXAMPLE 2 EFFECT OF THE S. THERMOPHILUS STRAIN CNCM 1-1520 ON THE LOAD OF H. PYLORI IN A MICE MODEL DETERMINED BY MICROBIOLOGICAL METHOD
  • the half stomachs were browed in 0,2ml physiological serum with a Potter (tube is weighed with the liquid with and without stomach to deduce the exact weigh of tissue), ⁇ . of dilutions (10 "1 to 10 "4 ) were spread on Petri dish containing pylori medium GSSA (Glaxo Selective Supplement A (20 ⁇ g/ml bacitracin, 1.07 ⁇ g/ml nalidixic acid, 0.33 ⁇ g/ml polymyxin B, and 10 ⁇ g /ml vancomycin) enriched with 10% blood. Bacterial count was earned out at 37°C after 5 to 7 days incubation under microaerobic condition. H. pylori was identified by phenotypic and biochemistry behaviors (morphology, urease and oxydase assays).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a strain of Streptococcus thermophilus or a cell fraction thereof for use in the treatment or prevention of Helicobacter pylori infection.

Description

STREPTOCOCCUS THERMOPHILUS STRAINS FOR TREATING HELICOBACTER
PYLORI INFECTION
The present invention relates to the field of probiotics. Particularly, the invention pertains to the use of a strain of Streptococcus thermophilics for the treatment or the prevention of Helicobacter pylori infection.
According to a definition recently approved by the National Yogurt Association (NY A) or the International Life Science Institute (ILSI) in the USA, probiotics are living micro-organisms which upon ingestion in a sufficient amount exert health benefits beyond basic nutrition. Probiotic bacteria have been described among species belonging to the genera Lactobacillus, Bifidobacterium, Streptococcus and Lactococcus, commonly used in the dairy industry. Probiotics are thought to intervene at the level of the gut microbiota by impeding the development of pathogenic microorganisms and/or by acting more directly on the immune system.
Helicobacter pylori (H. pylori) is a Gram-negative spiral-shaped bacteria that colonizes the human gastric mucus layer of more than 50% of the world's population. While the majority of individuals infected with H. pylori is asymptomatic although their gastric epithelium show sign of inflammation, 15% to 20% of H. pylori infected individuals develop diseases. Indeed, H. pylori is the major causative agent of chronic active gastritis, peptic ulcer diseases, atrophy, metaplasia, dysplasia, gastric cancer and gastric mucosa associated lymphoid tissue (MALT) lymphoma (see for review Fox and Wang, 2007 and Polk and Peek, 2010).
During infection, H. pylori binds specifically to gastric epithelial cells lining the gastric epithelium through several adhesion molecules (adhesins) produced by the bacteria, such as BabA and SabA proteins. Adhesion to the gastric epithelial cells protects the bacteria from liquid flow, peristaltic movement and shedding of the mucous layer. H. pylori adhesion to the gastric mucosa induces signal transduction pathways within the gastric epithelial cells, leading to gastric epithelial cell damages and atrophy via oxidative stress, apoptosis and/or autophagy mechanisms. Accordingly, H. pylori adhesion to gastric epithelial cells is a key step in the establishment of an infection of the gastric mucosa.
The standard treatment in patients infected with H. pylori is two antibiotics associated to a proton pump inhibitor (PPI), so called triple therapy. However, H. pylori eradication rate following triple therapy is dropping down because of antibiotic resistance or poor compliance. Further, despite several clinical trials, there is no effective vaccine available on the market yet.
It appears from the foregoing that there is a need for alternatives or complements to triple therapy for the treatment or for the prevention of H. pylori infection.
The use of probiotics has been proposed as alternatives or complements to triple therapy for treating or preventing H. pylori infection. For instance, Lactobacillus reuteri is considered as a candidate probiotic for inhibiting the growth of H. pylori since it produces the potent antimicrobial substance reuterin (3-hydroxypropionaldehyde) (International Application WO 2004/031368). Boyanova et al. (2009) have found several Lactobacillus delbrueckii subsp. bulgaricus strains that inhibit the growth of H. pylori strains in vitro. Simova et al. (2009) disclose a Lactobacillus delbrueckii strain (BB18) producing an inhibitory peptide (bacteriocin) and strongly inhibiting H. pylori. Linsalata et al. (2004) found that the Lactobacillus brevis strain CD2 is capable of reducing the intragastric H. pylori load, and suggested that it might be due to the elevated arginine deiminase activity of this strain, which would deprive H. pylori of arginine, and inhibit their growth and proliferation.
The inventors have found that the bacterial species Streptococcus thermophilus (S. thermophilics) is capable of decreasing the load of H. pylori strains in vivo.
Accordingly, a subject of the present invention is a Streptococcus thermophilus strain for use for treating or preventing Helicobacter pylori infection.
Said Streptococcus thermophilus can be used as a medicament, including a pharmaceutical composition and a functional food.
Said S. thermophilus strain is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori.
In a preferred embodiment, said S. thermophilus strain is the strain CNCM 1-1520. This strain was deposited by the Applicant, according to the Budapest Treaty, at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Docteur Roux, Paris) on December 30, 1994. This strain is disclosed in International Application WO 96/20607. This strain is also referred to as DN-001 147.
The present invention also encompasses mutant strains or genetically transformed strains derived from the parent strain CNCM 1-1520, provided that they are capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori. Method for assessing the capacity of a S. thermophilus strain to decrease the load of H. pylori strains in the stomach of a subject infected with H. pylori are described in the Examples below. These mutant or genetically transformed strains can be strains wherein one or more endogenous gene(s) of the parent strain CNCM 1-1520 has (have) been mutated, for instance to modify some of their metabolic properties (e.g. , their ability to ferment sugars, their resistance to acidity, their survival to transport in the gastrointestinal tract, their post-acidification properties or their metabolite production). They can also be strains resulting from the genetic transformation of the parent strain CNCM 1-1520 by one or more gene(s) of interest, for instance in order to give to said genetically transformed strains additional physiological features, or to allow them to express proteins of therapeutic or vaccinal interest that one wishes to administer through said strains. These mutant or genetically transformed strains can be obtained from the parent strain CNCM 1-1520 strain by means of the conventional techniques for random or site-directed mutagenesis and genetic transformation of Streptococcus, such as those described by Biswas et ah, 1993 and Maguin et ah, 1996, or by means of the technique known as "genome shuffling", such as described by Yu et al , 2008.
A subject of the present invention is also a cell fraction which can be obtained from a S. thermophilus strain capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori, preferably the strain CNCM 1-1520, provided that said cell fraction is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori, for use for treating or preventing H. pylori infection. Said cell fraction is in particular DNA preparations or bacterial wall preparations obtained from cultures of said strain. It may also be culture supernatants or fractions of these strains. The cell fractions suitable for this use can be chosen, for example, by testing their properties on the load of H. pylori strains in the stomach of a subject infected with H. pylori.
A subject of the present invention is also a composition comprising a Streptococcus thermophilus strain according to the present invention, preferably the strain CNCM 1-1520, or a cell fraction according to the present invention, for use for treating or preventing H. pylori infection.
In the composition of the invention, said strain can be used in the form of whole bacteria which may be living or dead. Alternatively, said strain can be used in the form of a bacterial lysate. Preferably the bacterial cells are present as living, viable cells.
The composition of the invention can be in any form suitable for administration, in particular oral administration. This includes for instance solids, semi-solids, liquids, and powders. Liquid composition are generally preferred for easier administration, for instance as drinks.
The composition can comprise at least 105 cfu, preferably at least 106 cfu, per gram dry weight, of at least one bacterial strain as mentioned above.
The composition can further comprise other strains of Streptococcus thermophilus and/or other strains of bacteria than the strains according to the present invention, in particular probiotic strain(s), such as Lactobacillus, Bifidobacterium and Lactococcus strain(s).
In a preferred embodiment, the composition comprises the Streptococcus thermophilus strain CNCM 1-1520, the Streptococcus thermophilus strain CNCM 1-1521 (also referred to as DN-001 339) and the Lactobacillus bulgaricus strain CNCM 1-1519 (also referred to as DN-100 182), and optionally a Lactobacillus paracasei strain, preferably the Lactobacillus paracasei subsp. paracasei CMCM 1-1518 (also referred to as DN-1 14 001). All these strains are described in International Application WO 96/20607.
When the bacteria are in the form of living bacteria, the composition may typically comprise 105 to 1013 colony forming units (cfu), preferably at least 106 cfu, more preferably at least 107 cfu, still more preferably at least 108 cfu, and most preferably at least 109 cfu per gram dry weight of the composition. In the case of a liquid composition, this corresponds generally to 104 to 1012 colony forming units (cfu), preferably at least 105 cfu, more preferably at least 106 cfu, still more preferably at least 107 cfu, and most preferably at least 109 cfu/ml.
The composition can be a pharmaceutical composition or a nutritional composition, including food products, food supplements and functional food. More particularly, the composition can be a medicament, including a pharmaceutical composition and a functional food.
A "food supplement" designates a product made from compounds usually used in foodstuffs, but which is in the form of tablets, powder, capsules, potion or any other form usually not associated with aliments, and which has beneficial effects for one's health. A "functional food" is an aliment which also has beneficial effects for one's health. In particular, food supplements and functional food can have a physiological effect - protective or curative - against a disease, for example against a chronic disease.
The nutritional composition according to the invention also includes a baby food, an infant milk formula or an infant follow-on formula. Preferably the present composition is a nutraceutical or a pharmaceutical product, a nutritional supplement or medical food. The composition can be a dairy product, preferably a fermented dairy product. The fermented product can be present in the form of a liquid or present in the form of a dry powder obtained by drying the fermented liquid. Examples of dairy products include fermented milk and/or fermented whey in set, stirred or drinkable form, cheese and yoghurt.
The fermented product can also be a fermented vegetable, such as fermented soy, cereals and/or fruits in set, stirred or drinkable forms.
In a preferred embodiment, the fermented product is a fresh product. A fresh product, which has not undergone severe heat treatment steps, has the advantage that the bacterial strains present are in the living form.
A subject of the present invention is also the use of a S. thermophilics strain as defined above, preferably the strain CNCM 1-1520, or a composition as defined above for the manufacture of a medicament for treating or preventing H. pylori infection.
A subject of the present invention is also a method for treating or preventing H. pylori infection in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a S. thermophilics strain as defined above, preferably the strain CNCM 1-1520, or a composition as defined above.
Determination of a therapeutically effective amount is well known from the person skilled in the art, especially in view of the detailed disclosure provided herein.
A subject of the present invention is also a method for the manufacture of a medicament for treating or preventing H. pylori infection, said method comprising incorporating a 5*. thermophilus strain as defined above, preferably the strain CNCM I- 1520, or a cell fraction as defined above, into at least one pharmaceutically acceptable diluent, carrier or excipient.
As used herein, the treatment or prevention encompasses inter alia: preventive infection and/or decreasing the load of H. pylori. The treatment or prevention also encompasses addressing at least one of the symptoms associated with H. pylori mentioned below.
Methods for diagnosing a H. pylori infection are known in the art. By way of example, diagnosis of a H. pylori infection can be made by checking by a blood antibody test, a stool antigen test or the carbon urea breath test. It can also be made by biopsy under endoscopy followed by an urease test, a histological examination, a microbial culture or a quantitative Real-Time PCR. The symptoms or diseases associated with H. pylori infection are stomach ache, abdominal pain, regurgitation, vomiting, belching, flatulence, nausea, chronic active gastritis, peptic ulcer diseases, atrophy, metaplasia, dysplasia, gastric cancer and gastric mucosa associated lymphoid tissue (MALT) lymphoma.
The present invention will be understood more clearly from the further description which follows, which refers to examples illustrating the capacity of the S. thermophilus strain CNCM 1-1520 of decreasing the load of H. pylori strains in vivo, as well as to the appended figures.
Figure 1 shows the change in the weight (in grams) of non infected mice, mice infected with H. pylori SSI receiving a control product, or infected with H. pylori SSI and treated with S. thermophilus strain CNCM 1-1520, measured just before the treatment (first bar), 3 weeks after the treatment (second bar) and just before sacrifice (third bar), obtained for 2 independent experiments.
Figure 2 shows the score of infection obtained by immunohistochemistry using anti-H. pylori antibodies in mice (i) non-infected with H. pylori, (ii) infected with H. pylori SSI receiving a control product (non- fermented milk) and (iii) infected with H. pylori SSI and treated with S. thermophilus CNCM 1-1520. Definition of scores: 0: no infected gland, 1 : rare infected glands, 2: 25% infected glands, 3 : from 25 to 50% infected glands, 4: > 50 % infected glands.
Figure 3 shows the quantification of H. pylori SSI DNA obtained by Real-Time
PCR in mice (i) non-infected with H. pylori, (ii) infected with H. pylori SSI but receiving a control product (non-fermented milk) and (iii) infected with H. pylori SSI and treated with S. thermophilus CNCM 1-1520.
Figure 4 shows the change in the weight (in grams) of non infected mice, mice infected with H. pylori SS I receiving a control product, or infected with H. pylori SSI and treated with S. thermophilus strain CNCM 1-1520, measured just before the treatment (first bar), 3 weeks after the treatment (second bar) and just before sacrifice (third bar), obtained for 2 independent experiments.
Figure 5 shows the quantification of H. pylori SS I obtained by bacterial culture on plate(in cfu (Colony Forming Unit) per gram of mice stomach) (i) non-infected with H. pylori, (ii) infected with H. pylori SS I but receiving a control product (non-fermented milk) and (iii) infected with H. pylori SS I and treated with S. thermophilus CNCM 1-1520. EXAMPLE 1: EFFECT OF THE S. THERMOPHILUS STRAIN CNCM 1-1520 ON
THE LOAD OF H. PYLORI IN A MICE MODEL DETERMINED BY
HISTOLOGICAL AND qRT-PCR METHODS
1.1 Material & Methods
Helicobacter pylori
H. pylori strain SS I having a very good colonization ability of mouse gastric mucosa (Lee et al., 1997) was used. Identity of the strain was checked by sequencing the genes glm, hspA and vacA (Raymond et al., 2004; Espinoza et al., 201 1 ; Zhang et al., 2007).
Streptococcus thermophilics
Milk product fermented by S. thermophilic strain CNCM 1-1520 was prepared as follows: First culture in M17 was prepared from frozen strain and incubated at 37°C for 17h. A second culture was prepared in skimmed milk enriched with yeast extract (2g/L) by inoculation at 1% from the first culture and incubated at 37°C for 17h. A third culture was prepared in milk enriched with yeast extract (2g/L) by inoculation at 1% from the second culture and incubation at 37°C until pH 4.7 was reached. The product was finally prepared by inoculation of milk enriched with yeast extract (2g/L) at 1% with the third culture until pH 4.8 was reached. Products were stored at -80°C. Bacterial count was carried out in Ml 7 after 48h incubation. Bacterial count was 1.5xl 09 cfu/mL.
Mice
40 BALB/cBy/J female mice of 5 weeks old (Charles River, France) and tested as SPF (« specific pathogen free ») were split into groups: 2 groups of 15 mice were infected and 1 group of 10 mice was used as non infected control. Mice were fed with food poor in vitamins to enhance the lesion development induced by H. pylori.
Infection (8 weeks)
6 weeks old mice received a hydric diet for 1 day and then were force-fed the following morning with 250 iL of an enriched suspension of the strain H. pylori SSI (1 to
2 Petri dishes of H. pylori for 5 mice). The mice were put in a cage with a normal diet. Then, the mice received a hydric diet again in the evening. This protocol was repeated for
3 days.
Treatment (6 weeks)
Eight weeks after their infection, mice were treated for 6 weeks with milk products containing S. thermophilics CNCM 1-1520. 120 g of milk product were given per cage per day in feeding-bottles instead of water. The feeding-bottles were changed every day. To assess the quantity of products ingested per animal, the feeding-bottles were weighed. Further, mice were weighted just before the treatment, 3 weeks after the treatment and just before sacrifice (results are shown in Figure 1).
Mice control groups received milk enriched with yeast extract (2g/L) (/. e. , without any S. thermophilics strain).
Sacrifices
Mice were sacrificed by cervical dislocation. Laparotomy was performed. Stomachs were isolated and gastric mucosa was washed in physiological serum.
Stomach was cut through the middle from the esophagus to the duodenum. For the right half stomach, cardia was eliminated, and then this half stomach was put in physiological serum to be used for the molecular study. The left half stomach was used for histology.
Histology
The left half stomach was fixed 1 night in 3.7% formol and washed with 70% ethanol and then paraffin-embedded and sectioned at 3 μηι thickness.
Immunohistochemistry was carried out with an antibody anti-H. pylori antigens: primary antibody: anti-H. pylori (Dako, Ref. B0471); secondary antibody and DAB: Dako EnVision+ System-HRP (DAB) (Dako, Ref. K401 1).
Molecular study fq RT-PCR)
Right stomachs were homogenized (disrupted) in 0.2 ml physiological serum with a Potter-Elvehjem (the tube was weighted with and without the stomach tissue to know the weight of the tissue).
Total DNA was extracted from the crushed stomach with Arrow Stool DNA kit (NorDiag, Norway) following supplier recommendations. For each crushed stomach total DNA was resuspended in 180 μΤ TRIS buffer (lOmM).
Presence of DNA of H. pylori was quantified in DNA extracts by Real-Time PCR. Amplification was done with primers targeting 23 S rRNA gene, present in two copies in H. pylori following the method described by Oleastro et al. (2003). For 20μ1 of mix (MgCl2 25mM, primers HPY-A et HPY-S 20μΜ described by Menard et al , 2002, sensor probe that is 5' labeled with LC-Red 640 and 3' phosphorylated and anchor probe that is 3 ' labeled with fluorescein (both probes described by Oleastro et al. 2003) 20μΜ, buffer containing the enzyme (10X, kit FastStart DNA Master Hybridization Probes, Roche Diagnostics), 5μ1 DNA at 200 ng/μΐ was added to be amplified in Light Cycler ROCHE, using the following program: Denaturation: 95°C lO min
Amplification: 50 cycles 20°C/sec
95°C 0 sec
60°C 20 s
72°C 12 sec
Fusion: 95°C 0 sec
38°C 50 sec 20°C/sec
1.2 Results
The scores of infection obtained by immunohistochemistry are shown in Figure 2. These results show that administration of a milk product fermented with the S. thermophilus strain CNCM 1-1520 to mice infected with H. pylori decreases (not significantly) the score of infection compared with the score obtained with the treatment with the milk control.
The results obtained by Real-Time PCR are shown in Figure 3. These results show that, in mice, the treatment with the milk product fermented with the S. thermophilus strain CNCM 1-1520 significantly decreases the load of H. pylori compared to the treatment with the milk control.
EXAMPLE 2: EFFECT OF THE S. THERMOPHILUS STRAIN CNCM 1-1520 ON THE LOAD OF H. PYLORI IN A MICE MODEL DETERMINED BY MICROBIOLOGICAL METHOD
2.1 Material & Methods
The material & methods for this experiment are the same as those described in
Example 1 above regarding the H. pylori strain, the S. thermophilus strain CNCM 1-1520, the mice, the infection, treatment and sacrifice of the mice, with the following exceptions:
- the bacterial count of S. thermophilus strain CNCM 1-1520 was 1.43.109 cfu/mL;
- the change in the weight of the treated mice is shown in Figure 4;
- only the right half stomach of the mice was used for the microbiology study. Microbiology study: culture of H. pylori
The half stomachs were browed in 0,2ml physiological serum with a Potter (tube is weighed with the liquid with and without stomach to deduce the exact weigh of tissue), ΙΟΟμί. of dilutions (10"1 to 10"4) were spread on Petri dish containing pylori medium GSSA (Glaxo Selective Supplement A (20 μg/ml bacitracin, 1.07 μg/ml nalidixic acid, 0.33 μg/ml polymyxin B, and 10μg /ml vancomycin) enriched with 10% blood. Bacterial count was earned out at 37°C after 5 to 7 days incubation under microaerobic condition. H. pylori was identified by phenotypic and biochemistry behaviors (morphology, urease and oxydase assays).
2.2 Results
The results obtained by microbiology for the S. thermophilus strain CNCM 1-1520 are shown in Figure 5. These results show that, in mice, the treatment with the milk product fermented with the strain CNCM 1-1520 significantly decreases the load of H. pylori compared to the treatment with the milk control.
REFERENCES - Biswas I. et al, J. Bacteriol. 1993; 175:3628-3635.
Boyanova L. et al , Lett Appl Microbiol. 2009; 48:579-84.
Espinoza MGC. et al, J. Clin. Microbiol. 201 1 ; 49: 1650-1652
Lee A. et al, Gastroenterology. 1997; 1 12: 1386-97.
Linsalata M. et al. , Helicobacter. 2004; 9: 165-172.
- Maguin E. et al, J. Bacteriol. 1996; 178:931 -935.
Menard A. et al, Antimicrob Agents Chemother. 2002; 46: 1 156-1 157.
Oleastro M. et al , J Clin Microbiol. 2003; 41 :397-402.
Raymond J. et al , Emerging Infection Deseases 2004; 10: 1815-1821.
Simonava et al , J Appl Microbiol. 2009; 106:692-701.
- Yu L. et al, J. Biotechnol. 2008; 134: 154-159.
Zhang et al , World J. Gastroenterol., 2007; 13 :845-850

Claims

1. A Streptococcus thermophilus strain for use for treating or preventing Helicobacter pylori infection.
2. A S. thermophilus strain according to claim 1, characterized in that said strain is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori.
3. A S. thermophilus strain according to claim 1 or claim 2, characterized in that it is the strain CNCM 1-1520.
4. A cell fraction obtained from a S. thermophilus strain as defined in any of claims 1 to 3, wherein it is capable of decreasing the load of H. pylori strains in the stomach of a subject infected with H. pylori, for use for treating or preventing H. pylori infection.
5. A composition comprising a S. thermophilus strain as defined in any of claims 1 to 3 or a cell fraction as defined in claim 4 for use for treating or preventing H. pylori infection.
6. The composition according to claim 5, characterized in that it comprises at least 105 cfu, preferably at least 106 cm, per gram dry weight, of a S. thermophilus strain as defined in any of claims 1 to 3.
7. The composition according to claim 5 or claim 6, characterized in that it is a nutritional composition.
8. The composition according to claim 7, characterized in that it is a dairy product.
EP12791860.5A 2012-10-25 2012-10-25 Streptococcus thermophilus strains for treating helicobacter pylori infection Withdrawn EP2912163A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/055883 WO2014064488A1 (en) 2012-10-25 2012-10-25 Streptococcus thermophilus strains for treating helicobacter pylori infection

Publications (1)

Publication Number Publication Date
EP2912163A1 true EP2912163A1 (en) 2015-09-02

Family

ID=47258048

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12791860.5A Withdrawn EP2912163A1 (en) 2012-10-25 2012-10-25 Streptococcus thermophilus strains for treating helicobacter pylori infection

Country Status (7)

Country Link
US (1) US20150284675A1 (en)
EP (1) EP2912163A1 (en)
JP (1) JP2016505239A (en)
CN (1) CN104769100A (en)
MX (1) MX2015005165A (en)
RU (1) RU2015119462A (en)
WO (1) WO2014064488A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183319A1 (en) * 2015-05-13 2016-11-17 University Of Florida Research Foundation, Incorporated Propionibacterium fruedenreichii as a probiotic for infants
CN112353822A (en) * 2020-11-18 2021-02-12 中国药科大学 Application of lactococcus lactis particles and probiotics in preparation of helicobacter pylori infection resisting medicine
CN113337431B (en) * 2021-06-04 2022-08-05 青岛诺森生物技术有限责任公司 Lactobacillus reuteri NSL0501 for inhibiting helicobacter pylori as well as biological agent and application thereof
CN116103197B (en) * 2022-12-19 2024-01-02 威凯海思(山东)生物工程有限公司 Streptococcus thermophilus with helicobacter pylori inhibiting effect and application thereof
CN119101635B (en) * 2024-11-11 2025-05-23 山东宠言生物科技有限公司 Helicobacter pylori resistant streptococcus salivarius subspecies thermophilus and its metaplasia and application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3174611B2 (en) * 1992-02-28 2001-06-11 明治乳業株式会社 Immunostimulating composition
ES2126962T3 (en) * 1995-01-02 1999-04-01 Gervais Danone Co LACTIC FERMENT, AND ITS USE FOR THE PREPARATION OF ANTIDIARRHEAL PRODUCTS.
FR2771600B1 (en) * 1997-11-28 2000-06-09 Gervais Danone Co PREPARATION OF FOOD PRODUCTS BY FERMENTATION OF A MIXTURE OF SOY JUICE AND CEREAL HYDROLYSAT BY STREPTOCOCCUS THERMOPHILUS
CA2334370A1 (en) * 1998-06-05 1999-12-16 Nobuyuki Suzuki Lactic acid bacterium-containing compositions, drugs and foods
FR2793257B1 (en) * 1999-05-06 2001-07-27 Gervais Danone Sa LACTIC BACTERIA WITH ANXIOLYTIC PROPERTIES, AND USES THEREOF
IT1311495B1 (en) * 1999-06-09 2002-03-13 Mendes S U R L COMPOSITION INCLUDING ALKALINE SPHYNOMYELINASE, USABLE AS A DIETARY PRODUCT, FOOD SUPPLEMENT OR MEDICATION.
IT1306716B1 (en) * 1999-06-21 2001-10-02 Mendes S U R L ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES.
US6464625B2 (en) * 1999-06-23 2002-10-15 Robert A. Ganz Therapeutic method and apparatus for debilitating or killing microorganisms within the body
US6444203B2 (en) * 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US9084434B2 (en) * 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
ES2526414T3 (en) * 2010-02-24 2015-01-12 Kabushiki Kaisha Yakult Honsha Method to build a new bacterium belonging to the genus Bifidobacterium
KR101310123B1 (en) * 2011-06-29 2013-09-23 가천대학교 산학협력단 Lactic acid bacteria group hindering growth of helicobactor pyloli
KR101364695B1 (en) * 2011-06-29 2014-02-19 가천대학교 산학협력단 Lactic acid bacteria group hindering growth of helicobactor pyloli

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHITRA N. WENDAKOON ET AL: "Reproduced with permission of the", DIGESTION, vol. 65, 1 January 2002 (2002-01-01), pages 16 - 20, XP055275978 *
PARK D ET AL: "M1117 The Effect of Probiotics and Mucoprotective Agents on PPI-Based Triple Therapy for Eradication of Helicobacter pylori", GASTROENTEROLOGY,, vol. 138, no. 5, 1 May 2010 (2010-05-01), pages S - 335, XP027024069, ISSN: 0016-5085, [retrieved on 20100427] *
See also references of WO2014064488A1 *

Also Published As

Publication number Publication date
JP2016505239A (en) 2016-02-25
US20150284675A1 (en) 2015-10-08
CN104769100A (en) 2015-07-08
WO2014064488A1 (en) 2014-05-01
MX2015005165A (en) 2015-10-29
RU2015119462A (en) 2016-12-20

Similar Documents

Publication Publication Date Title
Sanders et al. Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic
EP2848682B1 (en) Isolation, identification and characterization of strains with probiotic activity from the faeces of babies fed exclusively with breast milk
RU2567009C2 (en) Lactococcus lactis STRAIN FOR TREATMENT OR PREVENTION OF DIGESTION DISORDER AND THEREOF APPLICATION
KR102146429B1 (en) Strain of bifidobacterium animalis ssp. animalis
HK1044964A1 (en) Bifidobacterium in the treatment of inflammatory disease
KR101656208B1 (en) Composition for use in the prevention or treatment of inflammatory disease
EP2684469A1 (en) Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
AU2017327485B2 (en) Bacteria
CN117866831A (en) Lactobacillus rhamnosus and application thereof
CN109715181B (en) Bacteria
US20150284675A1 (en) Streptococcus thermophilus strains for treating helicobacter pylori infection
US9272007B2 (en) Strain of L. bulgaricus capable of inhibiting the adhesion of H. pylori strains to epithelial cells
CN104053766B (en) Produce the Lactobacillus brevis of reuterin
WO2013027087A1 (en) A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
US20050215471A1 (en) Compositions of bacteria and alpha-lactalbumin and uses thereof
Class et al. Patent application title: Strain of L. Bulgaricus Capable of Inhibiting the Adhesion of H. Pylori Strains to Epithelial Cells Inventors: Peggy Garault (Montlhery, FR) Peggy Garault (Montlhery, FR) Gaëlle Quere (Villebon Sur Yvette, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Francis Megraud (Bordeaux, FR) Assignees: COMPAGNIE GERVAIS DANONE
US20240050493A1 (en) Strains, compositions and methods of use
RU2708146C2 (en) Digestive agent
Paongphan et al. Characterization of probiotic lactic acid bacteria producing bile-salt hydrolase for development of fermented milk product

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160606

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170315